These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 33507815)

  • 1. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
    Korde LA; Somerfield MR; Carey LA; Crews JR; Denduluri N; Hwang ES; Khan SA; Loibl S; Morris EA; Perez A; Regan MM; Spears PA; Sudheendra PK; Symmans WF; Yung RL; Harvey BE; Hershman DL
    J Clin Oncol; 2021 May; 39(13):1485-1505. PubMed ID: 33507815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
    J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
    J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
    Schettini F; Nucera S; Brasó-Maristany F; De Santo I; Pascual T; Bergamino M; Galván P; Conte B; Seguí E; García Fructuoso I; Gómez Bravo R; Rivera P; Rodríguez AB; Martínez-Sáez O; Ganau S; Sanfeliu E; González-Farre B; Vidal Losada MJ; Adamo B; Cebrecos I; Mension E; Oses G; Jares P; Vidal-Sicart S; Mollà M; Muñoz M; Prat A
    ESMO Open; 2024 Jul; 9(7):103619. PubMed ID: 38943737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
    Mahtani R; Holmes FA; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Vogel C;
    Clin Breast Cancer; 2020 Jun; 20(3):e251-e260. PubMed ID: 32139271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
    J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
    Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
    Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
    Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM; Litvak A; Mayer EL; Pusztai L; Raab R; Wolff AC; Stearns V
    J Clin Oncol; 2022 Jun; 40(16):1816-1837. PubMed ID: 35439025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
    Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC
    J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Madigan LI; Dinh P; Graham JD
    Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
    Giordano SH; Temin S; Chandarlapaty S; Crews JR; Esteva FJ; Kirshner JJ; Krop IE; Levinson J; Lin NU; Modi S; Patt DA; Perlmutter J; Ramakrishna N; Winer EP; Davidson NE
    J Clin Oncol; 2018 Sep; 36(26):2736-2740. PubMed ID: 29939838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
    Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
    Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
    Jackisch C; Cortazar P; Geyer CE; Gianni L; Gligorov J; Machackova Z; Perez EA; Schneeweiss A; Tolaney SM; Untch M; Wardley A; Piccart M
    Cancer Treat Rev; 2021 Sep; 99():102229. PubMed ID: 34139476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
    J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.